Short answer
LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Convertible Notes and Warrants sold privately under Securities Act exemptions, limiting immediate liquidity and resale eligibility.
LIGAND PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Convertible Notes and Warrants sold privately under Securities Act exemptions, limiting immediate liquidity and resale eligibility
- Notes initially convertible into up to 2,670,010 common shares at 3.8143 shares per $1,000 principal amount
- Warrants initially exercisable for approximately 4.19 million common shares
- Potential maximum issuance of approximately 6.86 million shares creates material dilution risk
- Conversion and warrant share amounts subject to customary anti-dilution adjustments
Item 8.01 · Other Events
- $700 million aggregate principal amount of Notes priced and closed, including full exercise of $75 million additional purchase option
- Private placement to qualified institutional buyers under Rule 144A, providing substantial financing without a public offering
- Convertible note hedge and warrant transactions create potential future dilution and affect conversion economics
- Proceeds expected for company-directed uses, with details in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.2
- $625M upsized convertible notes at 0% interest, maturing September 15, 2031, preserving cash interest expense
- Approximately $605.3M net proceeds, supporting flexibility for investments including the previously announced XOMA Royalty acquisition
- $60M allocated to repurchase 228,859 shares at $262.17, partially offsetting potential conversion dilution
- Initial conversion price $334.27, a 27.5% premium; conversion hedge targets dilution while warrants may dilute above $524.34
- Initial purchasers can buy an additional $75M of notes during a 13-day option period
Other items in this filing:
- Item 2.03: Creation of a Direct Financial Obligation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIGAND PHARMACEUTICALS INC 8-K filings
Get the next LGND 8-K as it lands
Follow LGND for push alerts, or ask the research agent what this filing means.